Specific targeting of tau oligomers in Htau mice prevents cognitive impairment and tau toxicity following injection with brain-derived tau oligomeric seeds

Journal of Alzheimer's Disease

Volumn 40, Issue S1, 2014, Pages

  Castillo Carranza, Diana L ^a   Gerson, Julia E ^a   Sengupta, Urmi ^a   Guerrero Muñoz, Marcos J ^a   Lasagna Reeves, Cristian A ^a   Kayed, Rakez ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Alzheimer's disease; immunotherapy; propagation; seeding; tau oligomers; tauopathies

Indexed keywords

IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; RHODAMINE; TAU OLIGOMER SPECIFIC MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; TAU PROTEIN;

AMNESIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; LONG TERM CARE; MOUSE; NEUROFIBRILLARY TANGLE; NEUROTOXICITY; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN TARGETING; RECOGNITION; SPATIAL MEMORY; TAUOPATHY; WESTERN BLOTTING; WILD TYPE; ANIMAL; BRAIN; COGNITION DISORDERS; COMPLICATION; DISEASE MODEL; IMMUNOLOGY; METABOLISM; PATHOLOGY; TAUOPATHIES; TRANSGENIC MOUSE;

ANIMALS; BRAIN; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; IMMUNIZATION, PASSIVE; MICE; MICE, TRANSGENIC; TAU PROTEINS; TAUOPATHIES;

EID: 84901776466     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-132477     Document Type: Article

References (56)

1. Gomez-Isla T, Hollister R, West H, Mui S, Growdon JH, Petersen RC, Parisi JE, Hyman BT (1997) Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol 41, 17-24. (Pubitemid 27057088)
2. Kril JJ, Patel S, Harding AJ, HallidayGM(2002) Neuron loss from the hippocampus of Alzheimer's disease exceeds extracellular neurofibrillary tangle formation. Acta Neuropathol 103, 370-376. (Pubitemid 36097032)
3. Spires TL, Orne JD, SantaCruz K, Pitstick R, Carlson GA, Ashe KH, Hyman BT (2006) Region-specific dissociation of neuronal loss and neurofibrillary pathology in a mouse model of tauopathy. Am J Pathol 168, 1598-1607.
4. Haroutunian V, Davies P, Vianna C, Buxbaum JD, Purohit DP (2007) Tau protein abnormalities associated with the progression of Alzheimer disease type dementia. Neurobiol Aging 28, 1-7. (Pubitemid 44791636)
5. Polydoro M, Dzhala V, Pooler A, Nicholls S, McKinney AP, Sanchez L, Pitstick R, Carlson G, Staley K, Spires-Jones T, Hyman B (2014) Soluble pathological tau in the entorhinal cortex leads to presynaptic deficits in an early Alzheimer's disease model. Acta Neuropathol 127, 257-270.
6. Morsch R, Simon W, Coleman PD (1999) Neurons may live for decades with neurofibrillary tangles. J Neuropathol Exp Neurol 58, 188-197. (Pubitemid 29088942)
7. Berger Z, Roder H, Hanna A, Carlson A, Rangachari V, Yue M, Wszolek Z, Ashe K, Knight J, Dickson D, Andorfer C, Rosenberry TL, Lewis J, Hutton M, Janus C (2007) Accumulation of pathological tau species and memory loss in a conditional model of tauopathy. J Neurosci 27, 3650-3662. (Pubitemid 46557687)
8. Polydoro M, Acker CM, Duff K, Castillo PE, Davies P (2009) Age-dependent impairment of cognitive and synaptic function in the Htau mouse model of tau pathology. J Neurosci 29, 10741-10749.
9. Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Clos AL, Jackson GR, Kayed R (2011) Tau Oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice. Mol Neurodegener 6, 1-14.
10. SantaCruz K, Lewis J, Spires T, Paulson J,Kotilinek L, Ingelsson M, Guimaraes A, DeTure M, Ramsden M, McGowan E, Forster C, YueM, Orne J, Janus C, Mariash A, Kuskowski M, Hyman B, Hutton M, Ashe KH (2005) Tau suppression in a neurodegenerative mouse model improves memory function. Science 309, 476-481. (Pubitemid 40994688)
11. Spires-Jones TL, Kopeikina KJ, Koffie RM, de Calignon A, Hyman BT (2011) Are tangles as toxic as they look? J Mol Neurosci 45, 438-444.
12. Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TC, Maeda J, Suhara T, Trojanowski JQ, Lee VM (2007) Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53, 337-351. (Pubitemid 46161268)
13. Cowan CM, Quraishe S, Mudher A (2012) What is the pathological significance of tau oligomers? Biochem Soc Trans 40, 693-697.
14. Kopeikina KJ, Carlson GA, Pitstick R, Ludvigson AE, Peters A, Luebke JI, Koffie RM, Frosch MP, Hyman BT, Spires-Jones TL (2011) Tau accumulation causes mitochondrial distribution deficits in neurons in a mouse model of tauopathy and in human Alzheimer's disease brain. Am J Pathol 179, 2071-2082.
15. Sahara N, DeTure M, Ren Y, Ebrahim AS, Kang D, Knight J, Volbracht C, Pedersen JT, Dickson DW, Yen SH, Lewis J (2013) Characteristics of TBS-extractable hyperphosphorylated Tau species: Aggregation intermediates in rTg4510 mouse brain. J Alzheimers Dis 33, 249-263.
16. Andorfer C, Kress Y, Espinoza M, de Silva R, Tucker KL, Barde YA, Duff K, Davies P (2003) Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J Neurochem 86, 582-590. (Pubitemid 36897439)
17. Andorfer C, Acker CM, Kress Y, Hof PR, Duff K, Davies P (2005) Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms. J Neurosci 25, 5446-5454. (Pubitemid 40770926)
18. Maeda S, Sahara N, Saito Y, Murayama M, Yoshiike Y, Kim H, Miyasaka T, Murayama S, Ikai A, Takashima A (2007) Granular tau oligomers as intermediates of tau filaments. Biochemistry 46, 3856-3861. (Pubitemid 46493485)
19. Maeda S, Sahara N, Saito Y, Murayama S, Ikai A, Takashima A (2006) Increased levels of granular tau oligomers: An early sign of brain aging and Alzheimer's disease. Neurosci Res 54, 197-201. (Pubitemid 43276078)
20. Patterson KR, Remmers C, Fu Y, Brooker S, Kanaan NM, Vana L,Ward S, Reyes JF, Philibert K, Glucksman MJ, Binder LI (2011) Characterization of prefibrillar tau oligomers in vitro and in Alzheimer's disease. J Biol Chem 286, 23063-23076.
21. Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Sarmiento J, Troncoso J, Jackson GR, Kayed R (2012) Identification of oligomers at early stages of tau aggregation in Alzheimer's disease. FASEB J 26, 1946-1959.
22. Ward SM, Himmelstein DS, Lancia JK, Fu Y, Patterson KR, Binder LI (2013) TOC1: Characterization of a selective oligomeric tau antibody. J Alzheimers Dis 37, 593-602.
23. Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Sarmiento J, Troncoso J, Jackson GR, Kayed R (2012) Identification of oligomers at early stages of tau aggregation in Alzheimer's disease. FASEB J 26, 1946-1959.
24. Tai H-C, Serrano-Pozo A, Hashimoto T, Frosch MP, Spires-Jones TL, Hyman BT (2012) The synaptic accumulation of hyperphosphorylated tau oligomers in Alzheimer disease is associated with dysfunction of the ubiquitin-proteasome system. Am J Pathol 181, 1426-1435.
25. Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Clos AL, Jackson GR, KayedR(2011) Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice. Mol Neurodegener 6, 39.
26. Blair LJ, Nordhues BA, Hill SE, Scaglione KM, x, Leary JC, III, Fontaine SN, Breydo L, Zhang B, Li P, Wang L, Cotman C, Paulson HL, Muschol M, Uversky VN, Klengel T, Binder EB, Kayed R, Golde TE, Berchtold N, Dickey CA (2013) Accelerated neurodegeneration through chaperone-mediated oligomerization of tau. J Clin Invest 123, 4158-4169.
27. Frost B, Jacks RL, Diamond MI (2009) Propagation of tau misfolding from the outside to the inside of a cell. J Biol Chem 284, 12845-12852.
28. Gerson JE, Kayed R (2013) Formation and propagation of tau oligomeric seeds. Front Neurol 4, 93.
29. Wu JW, Herman M, Liu L, Simoes S, Acker CM, Figueroa H, Steinberg JI, Margittai M, Kayed R, Zurzolo C, Di Paolo G, Duff KE (2013) Small Misfolded tau species are internalized via bulk endocytosis and anterogradely and retrogradely transported in neurons. J Biol Chem 288, 1856-1870.
30. Lasagna-Reeves C, Castillo-Carranza DL, Sengupta U, Guerrero-Munoz MJ, Kiritoshi T, Neugebauer V, Jackson GR, Kayed R (2012) Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau. Sci Rep 2, 700.
31. Castillo-Carranza DL, Lasagna-Reeves CA, Kayed R (2013) Tau aggregates as immunotherapeutic targets. Front Biosci (Schol Ed) 5, 426-438.
32. Dodart J, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, DeLong CA, Wu S, Wu X, Holtzman DM, Paul SM (2002) Immunization reverses memory deficits without reducing brain A[beta] burden in Alzheimer's disease model. Nat Neurosci 5, 452-457. (Pubitemid 34454251)
33. Wilcock DM, Rojiani A, Rosenthal A, Subbarao S, Freeman MJ, Gordon MN, Morgan D (2004) Passive immunotherapy against A in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation 1, 24.
34. Racke MM, Boone LI, Hepburn DL, Parsadainian M, Bryan MT, Ness DK, Piroozi KS, Jordan WH, Brown DD, Hoffman WP, Holtzman DM, Bales KR, Gitter BD, May PC, Paul SM, DeMattos RB (2005) Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid. J Neurosci 25, 629-636.
35. Chai X,Wu S, Murray TK, KinleyR, CellaCV, Sims H, Buckner N, Hanmer J, Davies P, O'Neill MJ, Hutton ML, CitronM (2011) Passive immunization with anti-tau antibodies in two transgenic models: Reduction of tau pathology and delay of disease progression. J Biol Chem 286, 34457-34467.
36. Boutajangout A, Ingadottir J, Davies P, Sigurdsson EM (2011) Passive immunization targeting pathological phosphotau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J Neurochem 118, 658-667.
37. d'Abramo C, Acker CM, Jimenez HT, Davies P (2013) Tau passive immunotherapy in mutant P301L mice: Antibody affinity versus specificity. PLoS ONE 8, e62402.
38. Kelleher I, Garwood C, Hanger DP, Anderton BH, Noble W (2007) Kinase activities increase during the development of tauopathy in Htau mice. J Neurochem 103, 2256-2267. (Pubitemid 350173566)
39. McMillan P, Korvatska E, Poorkaj E, Evstafjeva Z, Robinson L, Greenup L, Leverenz J, Schellenberg GD, D'Souza I (2008) Tau isoform regulation is region and cell-specific in mouse brain. J Comp Neurol 511, 788-803.
40. Gotz J, Probst A, Spillantini MG, Schafer T, Jakes R, Burki K, Goedert M (1995) Somatodendritic localization and hyperphosphorylation of tau protein in transgenic mice expressing the longest human brain tau isoform. EMBO J 14, 1304-1313.
41. Karch CM, JengAT, GoateAM(2012) Extracellular tau levels are influenced by variability in tau that is associated with tauopathies. J Biol Chem 287, 42751-42762.
42. Spillantini MG, Goedert M (1998) Tau protein pathology in neurodegenerative diseases. Trends Neurosci 21, 428-433. (Pubitemid 28449072)
43. Hutton M (2001) Missense and splice site mutations in tau associated with FTDP-17: Multiple pathogenic mechanisms. Neurology 56, S21-S25. (Pubitemid 32539643)
44. Duff K, Knight H, Refolo LM, Sanders S, Yu X, Picciano M, Malester B, Hutton M, Adamson J, Goedert M, Burki K, Davies P (2000) Characterization of pathology in transgenic mice over-expressing human genomic and cDNA tau transgenes. Neurobiol Dis 7, 87-98. (Pubitemid 30241205)
45. Polydoro M, Acker CM, Duff K, Castillo PE, Davies P (2009) Age-dependent impairment of cognitive and synaptic function in the htau mouse model of tau pathology. J Neurosci 29, 10741-10749.
46. Dickstein D, Brautigam H, Stockton S, Jr., Schmeidler J, Hof P (2010) Changes in dendritic complexity and spine morphology in transgenic mice expressing human wild-type tau. Brain Struct Funct 214, 161-179.
47. Ma Q-L, Zuo X, Yang F, Ubeda OJ, Gant DJ, Alaverdyan M, Teng E, Hu S, Chen P-P, Maiti P, Teter B, Cole GM, Frautschy SA (2013) Curcumin suppresses soluble tau dimers and corrects molecular chaperone, synaptic, and behavioral deficits in aged human tau transgenic mice. J BiolChem 288, 4056-4065.
48. Lasagna-Reeves CA, Glabe CG, Kayed R (2011) Amyloid annular protofibrils evade fibrillar fate in Alzheimer disease brain. J Biol Chem 286, 22122-22130.
49. Lasagna-Reeves CA, Castillo-Carranza DL, Guerrero-Muñoz MJ, Jackson GR, Kayed R (2010) Preparation and characterization of neurotoxic tau oligomers. Biochemistry 49, 10039-10041.
50. Yanamandra K, Kfoury N, Jiang H, Mahan TE, Ma S, Maloney SE, Wozniak DF, Diamond MI, Holtzman DM (2013) Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron 80, 402-414.
51. Goldman SM, Tanner CM, Oakes D, Bhudhikanok GS, Gupta A, Langston JW (2006) Head injury and Parkinson's disease risk in twins. Ann Neurol 60, 65-72.
52. Chen H, Richard M, Sandler DP, Umbach DM, Kamel F (2007) Head injury and amyotrophic lateral sclerosis. Am J Epidemiol 166, 810-816. (Pubitemid 47428905)
53. Lehman EJ, Hein MJ, Baron SL, Gersic CM (2012) Neurodegenerative causes of death among retired National Football League players. Neurology 79, 1970-1974.
54. Ost M, Nylen K, Csajbok L, Ohrfelt AO, Tullberg M, Wikkelso C, Nellgard P, Rosengren L, Blennow K, Nellgard B (2006) Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury. Neurology 67, 1600-1604. (Pubitemid 44747930)
55. Ojo J-O, Mouzon B, GreenbergMB, Bachmeier C, Mullan M, Crawford F (2013) Repetitive mild traumatic brain injury augments tau pathology and glial activation in aged Htau mice. J Neuropathol Exp Neurol 72, 137-151.
56. Hawkins BE, Krishnamurthy S, Castillo-Carranza DL, Sengupta U, Prough DS, Jackson GR,DeWitt DS, KayedR(2013) Rapid accumulation of endogenous tau oligomers in a rat model of traumatic brain injury: Possible link between traumatic brain injury and sporadic tauopathies. J Biol Chem 288, 17042-17050.